Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01968265 | Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes | PHASE2 | COMPLETED | 38 | — | — | Oct 1, 2013 | May 1, 2015 | May 13, 2015 | 14 | Canada, Romania +1 |
Change from Baseline to Week 7
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| ISIS-GCCRRx | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ISIS-GCCRRx | DRUG | 3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin |
| Placebo | DRUG | 3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin |
Inclusion Criteria: * Male or female, age 18 to 75 * BMI greater than or equal to 25 * HbA1c greater than or equal to 7.5% and less than or equal to 10.5% * Type 2 Diabetes Mellitus and on stable dose of oral metformin * Agree to conduct home-based (fasted) blood glucose testing as directed Exclus...